Amphastar Q3 revenue up 50% to $180.6M; GAAP EPS $0.91, adj. $1.15

Amphastar Pharmaceuticals, Inc.

2023-Q3 EPS reported $1.91 revenue$466,290,000

Net revenues of $180.6M for Q3 2023, up from $120.1M in Q3 2022 (50% increase).
GAAP net income $49.2M ($0.91 diluted EPS) vs $15.9M ($0.30) a year ago.
Adjusted non-GAAP net income $61.9M ($1.15 diluted EPS) vs $20.2M ($0.38).
CEO attributes growth to diabetes portfolio, including BAQSIMI acquisition and generic glucagon.
Nine-month net revenues $466.3M vs $364.0M; GAAP net income $101.4M vs $57.5M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Amphastar Pharmaceuticals, Inc. reported three months ended September 30, 2023 results: revenue $180.6 million, net income $49.2 million, or $0.91 per share, EPS $0.91 per share.

Period: three months ended September 30, 2023
Revenue: $180.6 million
Net income: $49.2 million, or $0.91 per share
EPS: $0.91 per share
Result: reported results

Exact text from the filing

in such a filing. --- EX-99.1 (EX-99.1) --- Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 20 23 Reports Net Revenues of $180.6 Million for the Three Months Ended September 30, 2023 RANCHO CUCAMONGA, CA – November 8, 2023 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today

View on SEC.gov

Browse all earnings releases →

Amphastar Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001297184-23-000079

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.